Agilon Health, Inc. · NYSE:AGL
Agilon Health — Q2 2025 Earnings Presentation
11 slides from Agilon Health's earnings presentation, Aug 4, 2025
Slide 1: 2Q Earnings Presentation August 2025
2Q Earnings Presentation August 2025 Copyright © 2025 agilon health. Confidential internal document containing proprietary information. Do not distribute.
Slide 2: Disclaimers and Forward-Looking Statements
2 Disclaimers and Forward-Looking Statements FORWARD-LOOKING STATEMENTS AND OTHER INFORMATION Statements in this presentation that are not historical factual statements are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of th
Slide 3: Strengthening our Leadership
3 Jeff Schwaneke Chief Financial Officer Heidi Hittner EVP & Chief of Staff Dr. Karthik Rao Chief Medical Officer Ben Shaker Chief Markets Officer Girish Venkatachaliah Chief Technology Officer Denise Zamore Chief Legal Officer & Corporate Secretary Focus on Daily Delivery of Outcomes Consistent wit
Slide 4: Reinforcing our Focus on Execution
4 Reinforcing our Focus on Execution Executing strategic initiatives with a heightened sense of urgency and focus Accelerating strategic actions to deliver sustainable long-term profitability ✓ Amplifying initiatives to improve contract economics, reduce market risk, and optimize our cost structure
Slide 5: Key Priorities and Renewed Action Plan
Improved Executional Rigor Focused on Urgency, Accountability, and Performance • Deliver 4+ Star quality • Improved outcomes for high-risk patients • Clinical pathways expansion • Heightened focus on cost discipline • Alignment of spend with key priorities • Strong balance sheet with ~$327M1 in cash
Slide 6: Q2 2025 Highlights
6 Q2 2025 Highlights • Performance impacted by revised risk adjustment for 2024 and 2025 ▪ Total RAF impact of $85M, including $37M for FY’24, and $48M YTD in FY’25 ▪ Final and mid-year data highly correlated to enhanced data pipeline which went into effect at the end of Q1’25 ▪ Completed analysis o
Slide 7: Medical Margin Bridge – Q2 2025
Medical Margin Bridge – Q2 2025 Medical Margin Bridge for Actual vs. Guidance Q2 2025 Financial Summary • Medical margin for the quarter primarily impacted by lower prior year revenue development and updated current year revenue projections. • Prior Year Development (PYD): • Risk adjustment reflects
Slide 8: Q2 2025 Financial Performance
Quarter Ending June 30, 2025 Medicare Advantage Members 498,000 ACO Model Members 116,000 Total Members Live on Platform 614,000 Avg. Medicare Advantage Members 498,000 Total Revenues ($M) $1,395 Gross Profit ($M) ($52) Medical Margin ($M) ($53) Net Income (Loss) ($M) ($104) Adjusted EBITDA ($M) ($8
Slide 9: Non-GAAP Reconciliations
Non-GAAP Reconciliations 8 agilon health
Slide 10: Non-GAAP Reconciliations: Medical Margin
10 Non-GAAP Reconciliations (Dollars in thousands) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Gross profit (loss)(1) $ (52,427) $ 32,175 $ (1,705) $ 107,263 Other operating revenue (2,943) (3,179) (5,846) (6,338) Other medical expenses 2,164 76,523 82,357 161,947 Medic
Slide 11: Non-GAAP Reconciliations: Adjusted EBITDA
11 Non-GAAP Reconciliations (Dollars in thousands) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Net income (loss)(1) $ (104,370) $ (30,662) $ (92,258) $ (36,696) (Income) loss from discontinued operations, net of income taxes — — (14,000) 9,281 Interest expense 1,572 1,6